11/3/2026

speaker
Conference Operator
Operator

Good day, and thank you for standing by. Welcome to Denali Therapeutics' third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone, and you will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Laura Hansen, VP, Investor Relations.

speaker
Laura Hansen / Laura Chico
VP, Investor Relations / Wedbush Analyst

Good afternoon, everyone, and thank you for joining us to discuss Denali Therapeutics' third quarter 2026 financial results and business highlights. Earlier today, we issued our press release and filed our quarterly report. The press release and today's presentation are available in the Investor Relations section of our website. Before we begin, on slide two, I'd like to remind everyone that today's discussion includes forward-looking statements including our expectations for fourth quarter Avalaya net product revenue and the timing and availability of clinical data and any regulatory submissions. These statements reflect our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings and to the cautionary language in today's release and presentation. Denali undertakes no obligation to update these statements except as required by law. Joining me today are Ryan Watts, our Chief Executive Officer, Katie Peng, our Chief Commercial Officer, Peter Chin, our Chief Medical Officer and Head of Development, and Alexander Schuth, our Chief Operating and Financial Officer. Ryan will open with our progress this quarter. Katie will cover the Avalaya launch. Peter will review the clinical programs, and Alex will discuss our financial results before Ryan opens the Q&A session. Ryan.

speaker
Ryan Watts
Chief Executive Officer

Slide four. Thanks, Laura, and thank you all for joining us today. This was a defining quarter for Denali, and we are excited to share it with you. I want to start where we always do, with our purpose, transforming life for people living with serious disease. We are focused on making a real difference for children, adults, and families by delivering medicines across the blood-brain barrier and into the brain. In recent weeks, we have spent time with Hunter Syndrome families. Hearing directly what this disease asks of their children and what families hope Avalaya can offer brings our purpose into focus. Their trust is a responsibility we carry into the launch and into every program we advance. Slide five. It starts with Ablea, but it is bigger than one medicine. For the Hunter Syndrome community, Ablea is the first new FDA-approved therapy in nearly 20 years. It is the first FDA-approved medicine of its kind designed to cross the blood-brain barrier through the transferrin receptor and the first to come from our transport vehicle platform. That is a milestone for patients and a milestone for our field. Ablea gives Denali something we have worked toward for a long time, a commercial product that shows what our transport vehicle platform can do. That same delivery capability underpins a broad pipeline across rare and common diseases. Our ambition now is to repeat what we have achieved in Hunter Syndrome program after program. Slide six. You can see the breadth of that pipeline here. On the left are rare genetic diseases, including Hunter syndrome, Sanfilippo syndrome type A, FTD granulin, and Pompe disease. Together we estimate these diseases affect more than 30,000 people worldwide. On the right are Alzheimer's and Parkinson's disease, which we estimate affect more than 40 million. Different modalities, different diseases, one shared advantage, our ability to deliver medicines across the blood-brain barrier. Today we will focus on our most advanced enzyme replacement therapies in our Alzheimer's disease programs. Slide seven. Three things define this quarter, and each one moves us forward. First, Avalaya delivered 17.8 million in its second full commercial quarter, well ahead of our expectations. Katie will explain the adoption and access behind this result. Second, the Phase 1-2 study of Zephyrnophus Alpha in San Filippo Syndrome Type A has completed the pre-specified treatment duration for the primary endpoint. We are analyzing the data now and working toward a BLA submission in 2027 as we have planned. Third, both Alzheimer's programs are in the clinic with initial data expected in 2027. Together with readouts in Sanfilippo FTD Granulin and Pompe disease, those studies make next year a landmark year for the breadth of our platform. Katie, over to you.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation